In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Editorial Advisory Board
Ask The Analyst
FAQs
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Guidelines for Contributors
Report Store
UsernamePublicRestriction
Tags:
Leadership StartUps and SMEs Medical Device

Carlo Rivis: Know Your Own Value In Bringing Disruptive Innovation To Market

The Innovation Discovery CEO Has Made It His Role To Connect All The Dots In Delivering Novel Technology

  • Analysis

Executive Summary

Entrepreneur Carlo Rivis, one of In Vivo’s Rising Leaders, brought his disruptive innovation approaches to in-silico trials and digital avatar developer Computational Life, and now he is doing the same at Innovation Discovery.

You may also be interested in...



APACMed: Johnson & Johnson On Using ‘Big’ For Good In The COVID-19 Challenge

Johnson & Johnson's Ashley McEvoy explains how the global medtech business should change, seen through the lens of the coronavirus pandemic.

Philips Previews Five-Year Plan As Connected Care Returns Group To Growth In Q3

COVID-19 business volatility continues to impact the medtech industry, but Royal Philips is targeting modest comparable sales growth for 2020 after posting quarterly growth of 10%.

COVID-19 Antigen Tests Offer New Diagnostic Option In Germany

Germany’s COVID-19 testing strategy now permits the use and reimbursement of coronavirus antigen tests.

Table

View full table

Topics

Tags:
Leadership StartUps and SMEs Medical Device
UsernamePublicRestriction

Register

OM003387

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By